Akebia Therapeutics, Inc. (AX9.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John P. Butler MBA | CEO, President & Director | 1.72M | -- | 1964 |
| Mr. Erik John Ostrowski M.B.A. | Chief Business Officer, Senior VP, CFO & Treasurer | 367.89k | -- | 1972 |
| Dr. Steven Keith Burke M.D. | Senior VP of Research & Development and Chief Medical Officer | 918.6k | -- | 1961 |
| Mr. Nicholas Grund | Senior VP & Chief Commercial Officer | 609.77k | -- | 1970 |
| Mr. Richard C. Malabre | Chief Accounting Officer | -- | -- | 1961 |
| Ms. Kimberly Garko | Senior VP & Chief Technical Officer | -- | -- | -- |
| Ms. Tracey Vetterick | Vice President of Portfolio Strategy & Corporate Administration | -- | -- | -- |
| Mercedes Carrasco | Senior Director of Investor & Corporate Communications | -- | -- | -- |
| Ms. Carolyn Rucci | Senior VP of Legal, General Counsel & Secretary | -- | -- | -- |
| Ms. Meredith Bowman | Senior VP & Chief People Officer | -- | -- | -- |
Akebia Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 181
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
August 6, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Akebia Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available